Last reviewed · How we verify
ADP adoptive cell therapy — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
ADP adoptive cell therapy (ADP adoptive cell therapy) — USWM CT, LLC. Adoptive cell therapy that transfers immune cells to patients to enhance anti-tumor or anti-disease immune responses.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ADP adoptive cell therapy TARGET | ADP adoptive cell therapy | USWM CT, LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ADP adoptive cell therapy CI watch — RSS
- ADP adoptive cell therapy CI watch — Atom
- ADP adoptive cell therapy CI watch — JSON
- ADP adoptive cell therapy alone — RSS
Cite this brief
Drug Landscape (2026). ADP adoptive cell therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/adp-adoptive-cell-therapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing